Switch theme
Sign up to access all valuation multiples
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.
2006
83
LTM Revenue $57.2M
LTM EBITDA n/a
$620M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cormedix has a last 12-month revenue of $57.2M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cormedix achieved revenue of n/a and an EBITDA of -$46.2M.
Cormedix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cormedix valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $40.1M | XXX | XXX | XXX |
| Gross Profit | $42K | $0.1M | XXX | XXX | XXX |
| Gross Margin | Infinity% | 0% | XXX | XXX | XXX |
| EBITDA | -$46.2M | n/a | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | NaN% | XXX | XXX | XXX |
| Net Profit | -$28.2M | -$29.7M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -74% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 13, 2025, Cormedix's stock price is $11.
Cormedix has current market cap of $666M, and EV of $620M.
See Cormedix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $620M | $666M | XXX | XXX | XXX | XXX | $-0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 13, 2025, Cormedix has market cap of $666M and EV of $620M.
Cormedix's trades at 10.8x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Cormedix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cormedix and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $620M | XXX | XXX | XXX |
| EV/Revenue | 15.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | -29.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -15.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCormedix's NTM/LTM revenue growth is 140%
Cormedix's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Cormedix's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cormedix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cormedix and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cormedix acquired XXX companies to date.
Last acquisition by Cormedix was XXXXXXXX, XXXXX XXXXX XXXXXX . Cormedix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Cormedix founded? | Cormedix was founded in 2006. |
| Where is Cormedix headquartered? | Cormedix is headquartered in United States of America. |
| How many employees does Cormedix have? | As of today, Cormedix has 83 employees. |
| Who is the CEO of Cormedix? | Cormedix's CEO is Mr. Joseph Todisco. |
| Is Cormedix publicy listed? | Yes, Cormedix is a public company listed on NAS. |
| What is the stock symbol of Cormedix? | Cormedix trades under CRMD ticker. |
| When did Cormedix go public? | Cormedix went public in 2010. |
| Who are competitors of Cormedix? | Similar companies to Cormedix include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cormedix? | Cormedix's current market cap is $666M |
| What is the current revenue of Cormedix? | Cormedix's last 12-month revenue is $57.2M. |
| What is the current EV/Revenue multiple of Cormedix? | Current revenue multiple of Cormedix is 10.8x. |
| Is Cormedix profitable? | Yes, Cormedix is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
